30 closest matches · ranked by relevance
Asian Nose Enhancement
Primary: Percentage of Participants With a ≥ 1 Grade Improvement on the Assessment of Aesthetic Improvement Scale (AAIS) as Assessed by the Central Evaluating Physician at Day…
Perioral Rejuvenation · Upper Lip Projection
Primary: Nasal Tip Projection — 0.601 ratio
Nasal Augmentation
Primary: Mean Difference of Change in Volume (mL) at 6 Months After Baseline Versus Pre-treatment in the Nasal Dorsum/Nasal Root Between Restylane Perlane Treatment Group and…
Nose Enhancement
Primary: Volume Change From Baseline in the Nose Area — -0.005; 2.032 cubic centimeters (cc) — p=<0.0001
Breast Augmentation
Primary: Post Surgical Complications and Reoperation Rate During Breast Augmentation — 1.85; 1.85 percentage of participants
Nasal Obstruction
Primary: The Primary Efficacy Endpoint is the Percent of Treatment Responders — 101 Participants
Nasal Obstruction
Primary: Improvement in NOSE Score — 54.8 units on a scale — p=<0.0001
Conditions in T74.31 or T76.31
Primary: Soft and Hard Tissue Landmarks Movement — 0.95; -0.5; -0.95; -0.32 mm — p=0.098
Nasal Obstruction
Primary: Change From Baseline NOSE Score — 53.3; 48.1; 53.5 units on a scale — p=<0.0001
Nasal Valve Collapse
Primary: Implant-related Adverse Events — 5 participants
Nasal Obstruction
Primary: Change in NOSE Score — -44.5 units on a scale
Nasal Obstruction
Primary: Change in Peak Nasal Inspiratory Flow (PNIF) — 28; 24; 13; 27 liters per minute
Correction of the Moderate to Severe Nasolabial Folds
Primary: Percentage of NLFs With Treatment Success at Month 6 — 66.0; 72.8 Percentage of successfully treated NFLs
Subjects Requesting and Requiring an Open Rhinoplasty
Primary: Edema Severity — 1.25; 1.5; 1.25; 1 units on a scale
Nasal Septum Perforation
Primary: Mean Change in Post-operative Remucosalization at the Donor Site — 47.8; 37.8; 49.7; 43.5 percentage of remucosalization
Nasal Airway Obstruction
Primary: Incidence of Unanticipated Serious Adverse Device Effects — 0 events
Allergic Rhinitis
Primary: Change in Visual Analog Scale (VAS) From Baseline to 6 Weeks (6-week Value Compared to Baseline Value) — -8; -2 Scale points
Nasal Obstruction
Primary: Nasal Obstruction as Measured by Nasal Obstruction Symptom Evaluation (NOSE) Scores Following Therapy With Treatment (Triamcinolone Acetonide) and Placebo (Ayr Saline…
Pituitary Tumors
Primary: Change in Mean Survey Response From Baseline to 90 Days Post Surgery — 17.3; 13.5 units on a scale — p=0.001
Rhinoplasty
Primary: Live Assessment of Satisfaction With the Grafts — 2; 4 units on a scale
Healthy Volunteers
Primary: Percentage of Participants Improved in "Global Facial Aesthetic Appearance" - Judged by Participant — 95 percentage of participants
Malar Deficiency
Primary: Blinded Evaluations of First Impression — 7.35 score on a scale
Wrinkles
Primary: Number of Participants With Haematoma — 10; 23; 6; 11 Participants — p=<0.0001
Nasolabial Folds
Primary: Number Participants With Hypertropic Scarring, Keloid Formation, Hyper- or Hypopigmentation in Patients With Fitzpatrick Skin Types IV, V, and VI Receiving Nasolabial…
Chin Retrusion
Primary: Percentage of Participants (Responders) With At Least 1-Point Improvement From Baseline on the GCRS, as Assessed by the Blinded Evaluator at Month 6 ([Baseline…
Wrinkles
Primary: Keloid Formation at Site of Injection — 0.0 percentage of participants
Chin Augmentation · Chin Retrusion
Primary: Change From Baseline in the Blinded Evaluators' Live Assessment Using the Galderma Chin Retrusion Scale (GCRS) at Month 3 — -0.94; -1.02 score on a scale
Chronic Sinusitis
Primary: Device Success Rate — 14; 76; 10 ethmoid sinuses
Chronic Sinusitis · Polyposis
Primary: Olfaction — 20.2; 19.8 units on a scale
Lip Augmentation
Primary: Percentage of Participants Assessed as At Least 1-point Improvement From Baseline on Medicis Lip Fullness Scale (MLFS) — 94.7; 94.7 percentage of participants